tirzepatide gip agonist Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of 1 and GIP therapy GLP-1/GIP dual agonist tirzepatide normalizes

Li Y, Wu T, Wang Y, Yang L, Hu C, Chen L, et al

Other Warnings for SEMBOLIC 14 TABLET Before taking SEMBOLIC 14 TABLET, inform your doctor if you: Have or have had pancreatic problems Have a history of diabetes-related vision problems (diabetic retinopathy) Are planning to undergo or have recently undergone surgery Experience severe and persistent abdominal pain Have low blood sugar (hypoglycaemia) Notice sudden changes in vision Have delayed gastric emptying (gastroparesis) Have gastrointestinal issues, such as severe vomiting, diarrhoea, or dehydration Have gallbladder problems Who should not take SEMBOLIC 14 TABLET SEMBOLIC 14 TABLET is not recommended for use if you: Have a personal or family history of medullary thyroid carcinoma (MTC) Have an endocrine disorder known as Multiple Endocrine Neoplasia syndrome type 2 (MEN2) Have type 1 diabetes Have developed diabetic ketoacidosis Drug - Drug interaction Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements

Reduced saliva, slowed digestion, acid reflux, and ketone release from fat burning can all play a role

Key points 1

Common side effects of compounded semaglutide include nausea, vomiting, diarrhea, and stomach pain